Capri EGM acquires R&D build-to-suit for National Resilience

By The Science Advisory Board staff writers

February 28, 2022 -- Real estate investment manager Capri EGM has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience.

Ology Bioservices, a wholly-owned subsidiary of Resilience, and the operator of the lab & research facility has recently been awarded a contract valued at $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT). Resilience also has a multi-year agreement to produce mRNA for Moderna’s COVID-19 vaccine, a strategic multi-year R&D alliance with Harvard University to develop complex medicines and a multi-product biomanufacturing development agreement with Takeda Pharmaceutical supporting their plasma-derived medicines portfolio. The Resilience Lab & Research build-to-suit is strategically located in North Florida’s Research and Life Science cluster. Capri EGM is an established real estate investment company specializing in corporate build-to-suit and sale leaseback financing and the acquisition of income-generating logistics, life science, and R&D corporate real estate in high-growth markets throughout the U.S. National Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. No financial details of the deal were disclosed.
Resilience to acquire Bluebird facility, partner on vector manufacturing
Bluebird Bio and National Resilience have formed a strategic alliance to accelerate the early research, development, and delivery of next-generation cell...
VBI provides COVID-19 vaccine updates amid supply chain delays
VBI Vaccines has provided preclinical updates on its two COVID-19 vaccine programs: VBI-2901, a trivalent pan-coronavirus vaccine candidate, and VBI-2902,...

Copyright © 2022 scienceboard.net


Conferences
Cell Bio 2022
December 3-7
District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter